The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
In a controversial move, NIH officials may be pushing to eliminate mRNA vaccine technology from grant applications, signaling a potential halt in vital medical research. Scientists express fears over job security and funding.
